Sex Hormone Levels, Breast Cancer Risk, and Cancer Receptor Status in Postmenopausal Women: the ORDET Cohort
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background: Endogenous sex hormone levels have been associated with increased breast cancer risk in postmenopausal women in several prospective studies. However, it remains unclear to what extent serum hormone-breast cancer associations differ with receptor status. Methods: Associations between serum sex hormone levels and breast cancer risk were assessed in a nested case-control study on postmenopausal women of the ORDET cohort. After a median follow-up of 13.5 years, 165 women developed breast cancer. Relative risks of developing breast cancer were estimated by conditional logistic regression. Results: Total and free testosterone levels were directly associated with breast cancer risk [relative risk, 3.28 (95% confidence interval, 1.93-5.55) and 2.86 (95% confidence interval, 1.66-4.94), respectively, for highest versus lowest quartile]. When relations between hormone level and risk of breast cancer expressing various receptor combinations were assessed, high total testosterone was significantly associated with increased risk of estrogen receptor–positive cancers, irrespective of progesterone receptor status. High total testosterone was also associated with increased risk of both human epidermal growth factor receptor 2 (HER2)–negative (HER2−) and HER2+ cancers. High estradiol tended to be associated with increased risk of HER2− cancer and inversely associated with HER2+ cancer, with significant (P = 0.027) heterogeneity between HER2+ and HER2− cancers. However, there were relatively few HER2+ cases. Conclusions: This study provides further evidence that high levels of circulating testosterone increase the risk of developing breast cancer in postmenopausal women. The cancers that develop are mainly estrogen receptor positive. Although HER2+ and HER2− breast cancers were both associated with high total testosterone, they showed opposing associations with estrogen. (Cancer Epidemiol Biomarkers Prev 2009;18(1):169–76)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women
Endogenous Hormones Breast Cancer Collaborative Group (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg022 · Cited by 1,093 · cited 1×
“These findings are in direct contrast to those of a collaborative analysis of eight prospective studies (21), which indicated increased breast cancer risk with increasing BMI in postmenopausal women, which was largely explained by an increase in estrogens with BMI.”
ResultLow sex hormone-binding globulin is associated with the metabolic syndrome in postmenopausal women
Weinberg, M. E., Manson, J. E., Buring, J. E., Cook, N. R., Seely, E. W., Ridker, P. M., & Rexrode, K. M. (2006) · Metabolism · doi:10.1016/j.metabol.2006.06.017 · Cited by 101 · cited 1×
“In women, metabolic syndrome is associated with increased testosterone levels (24, 25).”
Background
Cited by
Picon‐Ruiz, M., Morata‐Tarifa, C., Valle‐Goffin, J. J., Friedman, E. R., & Slingerland, J. M. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21405 · Cited by 893
Collins, L. C., Cole, K. S., Marotti, J. D., Hu, R., Schnitt, S. J., & Tamimi, R. M. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.54 · Cited by 387
Androgen therapy in women: a reappraisal: an Endocrine Society Clinical Practice Guideline
Wierman, M. E., Arlt, W., Basson, R., Davis, S. R., Miller, K. K., Murad, M. H., Rosner, W., & Santoro, N. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2260 · Cited by 363
Pathogenesis, prevention, diagnosis and treatment of breast cancer
Shah, R. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i3.283 · Cited by 329
Physical Activity and Breast Cancer Prevention
Lynch, B. M., Neilson, H. K., & Friedenreich, C. M. (2010) · Recent Results in Cancer Research · doi:10.1007/978-3-642-04231-7_2 · Cited by 282
Metadata
- Authors
- Sieri, S., Krogh, V., Bolelli, G., Abagnato, C. A., Grioni, S., Pala, V., Evangelista, A., Allemani, C., Micheli, A., Tagliabue, G., Schunemann, H. J., Menard, S., Berrino, F., & Muti, P.
- Venue
- Cancer Epidemiology, Biomarkers & Prevention
- Published
- 2009-01-01
- Volume
- 18
- Issue
- 1
- Pages
- 169-176
- ISSN
- 1055-9965 (ISSN-L)
- 1538-7755
- OpenAlex
- W2025285625
- Cited by
- 123
- References
- 2
- FWCI
- 5.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sex Hormone Levels, Breast Cancer Risk, and Cancer Receptor Status in Postmenopausal Women: the ORDET Cohort. https://app.cochat.ai/papers/10.1158/1055-9965.epi-08-0808
- The paper
- Sieri, S., Krogh, V., Bolelli, G., Abagnato, C. A., Grioni, S., Pala, V., Evangelista, A., Allemani, C., Micheli, A., Tagliabue, G., Schunemann, H. J., Menard, S., Berrino, F., & Muti, P. (2009). Sex Hormone Levels, Breast Cancer Risk, and Cancer Receptor Status in Postmenopausal Women: the ORDET Cohort. Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-08-0808
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.